↓ Skip to main content

Oncotarget

Article Metrics

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease

Overview of attention for article published in Oncotarget, January 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#47 of 13,609)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
11 news outlets
blogs
2 blogs
twitter
71 tweeters
patent
6 patents
facebook
10 Facebook pages
googleplus
6 Google+ users
video
1 video uploader

Citations

dimensions_citation
286 Dimensions

Readers on

mendeley
429 Mendeley
Title
Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
Published in
Oncotarget, January 2015
DOI 10.18632/oncotarget.3174
Pubmed ID
Authors

Rebecca Lamb, Bela Ozsvari, Camilla L. Lisanti, Herbert B. Tanowitz, Anthony Howell, Ubaldo E. Martinez-Outschoorn, Federica Sotgia, Michael P. Lisanti

Abstract

Here, we propose a new strategy for the treatment of early cancerous lesions and advanced metastatic disease, via the selective targeting of cancer stem cells (CSCs), a.k.a., tumor-initiating cells (TICs). We searched for a global phenotypic characteristic that was highly conserved among cancer stem cells, across multiple tumor types, to provide a mutation-independent approach to cancer therapy. This would allow us to target cancer stem cells, effectively treating cancer as a single disease of "stemness", independently of the tumor tissue type. Using this approach, we identified a conserved phenotypic weak point - a strict dependence on mitochondrial biogenesis for the clonal expansion and survival of cancer stem cells. Interestingly, several classes of FDA-approved antibiotics inhibit mitochondrial biogenesis as a known "side-effect", which could be harnessed instead as a "therapeutic effect". Based on this analysis, we now show that 4-to-5 different classes of FDA-approved drugs can be used to eradicate cancer stem cells, in 12 different cancer cell lines, across 8 different tumor types (breast, DCIS, ovarian, prostate, lung, pancreatic, melanoma, and glioblastoma (brain)). These five classes of mitochondrially-targeted antibiotics include: the erythromycins, the tetracyclines, the glycylcyclines, an anti-parasitic drug, and chloramphenicol. Functional data are presented for one antibiotic in each drug class: azithromycin, doxycycline, tigecycline, pyrvinium pamoate, as well as chloramphenicol, as proof-of-concept. Importantly, many of these drugs are non-toxic for normal cells, likely reducing the side effects of anti-cancer therapy. Thus, we now propose to treat cancer like an infectious disease, by repurposing FDA-approved antibiotics for anti-cancer therapy, across multiple tumor types. These drug classes should also be considered for prevention studies, specifically focused on the prevention of tumor recurrence and distant metastasis. Finally, recent clinical trials with doxycycline and azithromycin (intended to target cancer-associated infections, but not cancer cells) have already shown positive therapeutic effects in cancer patients, although their ability to eradicate cancer stem cells was not yet appreciated.

Twitter Demographics

The data shown below were collected from the profiles of 71 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 429 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 6 1%
United Kingdom 3 <1%
Canada 2 <1%
Portugal 1 <1%
Sweden 1 <1%
South Africa 1 <1%
France 1 <1%
Turkey 1 <1%
Singapore 1 <1%
Other 4 <1%
Unknown 408 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 92 21%
Researcher 88 21%
Student > Master 59 14%
Student > Bachelor 55 13%
Other 26 6%
Other 59 14%
Unknown 50 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 119 28%
Biochemistry, Genetics and Molecular Biology 89 21%
Medicine and Dentistry 71 17%
Chemistry 24 6%
Pharmacology, Toxicology and Pharmaceutical Science 12 3%
Other 48 11%
Unknown 66 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 167. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 May 2021.
All research outputs
#142,075
of 18,238,764 outputs
Outputs from Oncotarget
#47
of 13,609 outputs
Outputs of similar age
#2,220
of 300,165 outputs
Outputs of similar age from Oncotarget
#1
of 327 outputs
Altmetric has tracked 18,238,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,609 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,165 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 327 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.